Since 2017, research at the Catalan Institute for Nanoscience and Nanotechnology has shown remarkable potential for real-world applications. The novel material developed exhibits a strong safety and preliminary efficacy profile across multiple medical fields, ranging from tissue regeneration to serving as a platform for delivering cell lines and small-molecule drugs.

This platform technology possesses several key features that make it adaptable to various applications:

• Micron-thin membrane that conforms seamlessly to tissue surfaces.
• Adhesion properties suitable for wet surfaces, such as tissues within the human body.
• Biocompatibility that supports cell proliferation, migration, and differentiation.
• Antimicrobial properties.
• Degradability profile that supports regeneration, eventually being metabolized and absorbed by the body.

Tirecat Health was founded to translate this cutting-edge science from Spanish research institutions into practical solutions. The company’s mission is to provide innovative therapeutic and diagnostic tools to address unmet medical needs. While numerous challenges lie ahead, Tirecat Health is actively preparing for the clinical phase to demonstrate how the promising benefit-risk profile of this technology can translate to human treatments.